135,807 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Acquired by Two Sigma Investments LP

Two Sigma Investments LP acquired a new stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 135,807 shares of the company's stock, valued at approximately $560,000. Two Sigma Investments LP owned about 0.18% of Trevi Therapeutics at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of TRVI. Point72 Asset Management L.P. purchased a new position in Trevi Therapeutics during the 4th quarter valued at about $17,099,000. Vivo Capital LLC grew its position in shares of Trevi Therapeutics by 116.3% in the 4th quarter. Vivo Capital LLC now owns 3,487,903 shares of the company's stock worth $14,370,000 after buying an additional 1,875,000 shares during the last quarter. MPM Bioimpact LLC increased its stake in shares of Trevi Therapeutics by 101.2% during the fourth quarter. MPM Bioimpact LLC now owns 3,094,896 shares of the company's stock valued at $12,751,000 after buying an additional 1,556,379 shares during the period. Adage Capital Partners GP L.L.C. bought a new position in shares of Trevi Therapeutics during the fourth quarter valued at approximately $10,300,000. Finally, Acorn Capital Advisors LLC bought a new position in shares of Trevi Therapeutics during the fourth quarter valued at approximately $8,244,000. 95.76% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Jennifer L. Good sold 5,263 shares of Trevi Therapeutics stock in a transaction dated Friday, March 21st. The stock was sold at an average price of $6.58, for a total value of $34,630.54. Following the completion of the transaction, the chief executive officer now owns 213,313 shares of the company's stock, valued at $1,403,599.54. The trade was a 2.41% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 18.30% of the company's stock.

Analyst Ratings Changes

TRVI has been the topic of a number of research analyst reports. D. Boral Capital reissued a "buy" rating and set a $21.00 price objective on shares of Trevi Therapeutics in a research report on Monday, June 2nd. Oppenheimer reaffirmed an "outperform" rating on shares of Trevi Therapeutics in a research note on Monday, June 2nd. HC Wainwright started coverage on shares of Trevi Therapeutics in a research note on Wednesday, May 28th. They issued a "buy" rating and a $21.00 price target for the company. Raymond James upgraded shares of Trevi Therapeutics from an "outperform" rating to a "strong-buy" rating and raised their price objective for the stock from $9.00 to $29.00 in a report on Monday, March 10th. Finally, Wall Street Zen cut Trevi Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $18.63.

Trevi Therapeutics Trading Up 1.6%

TRVI traded up $0.10 during midday trading on Tuesday, reaching $6.51. The company's stock had a trading volume of 1,362,722 shares, compared to its average volume of 1,332,067. Trevi Therapeutics, Inc. has a 1 year low of $2.30 and a 1 year high of $7.48. The stock's 50-day moving average is $6.26 and its 200-day moving average is $5.04. The firm has a market capitalization of $650.30 million, a price-to-earnings ratio of -14.80 and a beta of 0.59.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.04. As a group, equities research analysts forecast that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current fiscal year.

Trevi Therapeutics Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.